Endocyte (ECYT) in Focus: Stock Tumbles 8.3% - Tale of the Tape - Grifols (NASDAQ:GRFS)

Endocyte, Inc. ECYT saw a big move last session, as the company's shares fell more than 8.0% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This reverses the recent trend for ECYT as the stock is now up more than 75.0% in the past one-month time frame.

Although this slump was obviously disappointing, the company has seen 3 positive revisions and its current year earnings consensus has moved higher over the past few weeks. This suggests that the recent slump might be a temporary blip on the radar for ECYT. So make sure to keep an eye on this stock going forward to see if yesterday's price decline is confirmed by more weakness, or if it can rebound in the weeks ahead.

ECYT currently has a Zacks Rank #3 (Hold) while its Earnings ESP is zero.

Some better-ranked stocks in the healthcare sector include Questcor Pharmaceuticals, Inc. QCOR, Grifols, S.A. GRFS and Lannett Company, Inc. LCI. All these stocks carry a Zacks Rank #1(Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

ENDOCYTE INC ECYT: Free Stock Analysis Report

GRIFOLS SA-ADR GRFS: Free Stock Analysis Report

LANNETT INC LCI: Free Stock Analysis Report

QUESTCOR PHARMA QCOR: Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Market News and Data brought to you by Benzinga APIs